remdesivir - versus control - for COVID-19 pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.86 [0.37, 2.01]< 10%3 studies (3/-)63.5 %some concernnot evaluable moderatecrucial-
deaths 0.83 [0.63, 1.09]< 126%6 studies (6/-)91.3 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 0.75 [0.50, 1.12]< 152%4 studies (4/-)92.2 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.95 [0.55, 1.64]< 10%1 study (1/-)57.3 %lownot evaluable highimportant-
clinical improvement 1.30 [1.15, 1.46]> 10%4 studies (4/-)100.0 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.49 [1.13, 1.98]> 10%3 studies (3/-)99.7 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.45 [1.18, 1.79]> 10%4 studies (4/-)100.0 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.19 [0.91, 1.58]> 10%3 studies (3/-)89.6 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.22 [1.11, 1.35]> 10%4 studies (4/-)100.0 %some concernnot evaluable moderateimportant-
death or ventilation 0.97 [0.85, 1.10]< 10%1 study (1/-)67.8 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.87 [0.39, 1.96]< 129%4 studies (4/-)63.1 %some concernnot evaluable moderateimportant-
recovery 1.15 [0.99, 1.33]> 10%2 studies (2/-)96.4 %some concernnot evaluable moderatenon important-

safety endpoints 00

AE leading to drug discontinuation 2.43 [0.79, 7.45]< 10%1 study (1/-)6.0 %lownot evaluable highimportant-
serious adverse events 0.67 [0.53, 0.85]< 10%4 studies (4/-)99.9 %some concernnot evaluable moderateimportant-
adverse events 1.40 [1.05, 1.87]< 14%2 studies (2/-)1.0 %some concernnot evaluable moderatenon important-
deep vein thrombosis 0.62 [0.23, 1.64]< 10%2 studies (2/-)83.1 %some concernnot evaluable moderatenon important-
elevated liver enzymes 0.58 [0.34, 0.97]< 16%2 studies (2/-)98.1 %some concernnot evaluable moderatenon important-
hyperbilirubinemia 0.97 [0.48, 1.93]< 10%2 studies (2/-)53.8 %some concernnot evaluable moderatenon important-
pulmonary embolism 0.82 [0.20, 3.29]< 10%2 studies (2/-)61.1 %some concernnot evaluable moderatenon important-
renal impairment 1.02 [0.64, 1.61]< 10%2 studies (2/-)47.2 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.